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SUMMARY
Introduction Statins have similar side effects that do not always occur at the same rate among the vari-
ous statins. We present a case of simvastatin-induced muscle toxicity that disappeared when pravastatin 
was substituted for the original drug.
Case Outline A 74-year-old male, a nonsmoker, complained of severe nocturnal leg cramps. The patient 
also complained that similar painful cramping occurred when he walked rapidly or jogged. Because 
some components of his lipid panel exceeded the ‘desirable’ range, and as he had a history of myocardial 
infarction, his family physician prescribed simvastatin (40 mg/day). The patient had taken this medica-
tion for the past eight years. The painful nocturnal episodes started two years ago and affected either 
one or the other leg. Four months ago we discontinued his simvastatin and prescribed pravastatin (80 
mg/day). At a follow-up visit six weeks later, the patient reported that his leg pains at night and the pain 
experienced after brisk walking had disappeared. Four months after the substitution of pravastatin for 
simvastatin, the patient reported that his complete lack of symptoms had continued.
Conclusion These painful muscle cramps were probably caused by an inadequate vascular supply to 
the calf and foot muscles. Perhaps a combination of advanced age and atherosclerotic changes created 
a predisposition for the simvastatin-induced leg cramps. Pravastatin differs from simvastatin in several 
ways. It is not metabolized by cytochrome P450 (CYP) 3A4 oxidases, and thus is not influenced by CYP 3A4 
inhibitors like simvastatin. Also, simvastatin is associated with single-nucleotide polymorphisms located 
within the SLCO1B1 gene on the chromosome 12 and established myopathy, while pravastatin lacks this 
association. These differences may contribute to increased tolerance to pravastatin in this particular case.
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INTRODUCTION
Statins reduce cardiovascular events both in 
primary and secondary prevention of lipid 
abnormalities [1]. These drugs (atorvastatin, 
fluvastatin, lovastatin, pravastatin, and simvas-
tatin) may have similar muscular side effects, 
but these effects do not always occur at the 
same rate among various statins. The muscular 
pain and cramping associated with statin use 
may lead patients to stop taking their drug, but 
discontinuation may cause a negative rebound 
effect related to the vascular events. We present 
a case of severe simvastatin-induced nocturnal 
leg cramps in an elderly patient who experi-
enced relief and disappearance of the symp-
toms after the substitution of pravastatin for 
simvastatin.
CASE REPORT
A 74-year-old male, who never smoked, com-
plained of severe leg pain at night; this oc-
curred once or twice each night at a frequency 
of three or more times a week. The pain abated 
within several minutes if he stood or walked 
around. The patient described these events, 
which occurred in only one leg at a time, as 
extremely painful, almost unbearable, cramps 
of his calves and feet.
These nocturnal episodes started two years 
ago. At first, they occurred just a few times a 
month, and the patient thought they were relat-
ed to his advanced age and glucose intolerance. 
When he finally sought medical attention, his 
family physician advised him to use magne-
sium carbonate, an over-the-counter medicine, 
to prevent the attacks. Daily usage of magne-
sium carbonate effervescent tablets (300 mg) 
did not help, but the patient had taught himself 
to diminish the severity of the attacks by get-
ting up and standing for a while. The patient 
also complained that similar painful leg cramp-
ing occurred when he walked rapidly or jogged 
for approximately five to ten minutes. When he 
stopped, the pain quickly subsided. In contrast 
to the nocturnal leg cramping, the pain associ-
ated with jogging affected both legs at a time.
The patient’s history included glucose intol-
erance, persisting for the past twenty years, and 
moderate obesity. Two years ago, he had a myo-
cardial infarction (MI). He was admitted to the 
hospital, but refused coronary arteriography.   
Two of his four older sisters had type 2 diabetes 
that appeared when they were in their sixties.   
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When our patient gradually increased his physical activity 
and changed his diet, his body weight reduced to normal. 
Ten years ago, his diastolic pressure increased slightly (92-
94 mmHg measured over several visits to his doctor), but 
since that time, his blood pressure has been well regulated 
by treatment with lisinopril (10 mg/day) and atenolol (25 
mg/day). Because his lipid panel was not within ‘desir-
able’ limits, and because of his previous MI, his family 
physician prescribed simvastatin (40 mg/day, to be taken 
at night). The values of triglyceride and LDL cholesterol 
soon reached normal levels. The values of HDL cholesterol 
were lower than desirable but still slightly improved (Table 
1). The patient had been taking simvastatin for eight years 
by the time we saw him.
The patient maintained glycemic control with diet alone, 
but his glycohemoglobin (HbA1c) increased slightly over a 
six-year period: 5.5% in 2006, 5.8% in 2009, 6.5% in 2011, 
and 7.1% in 2012 (normal range: 4.0-6.2%). The results of 
other blood tests were within normal range, including the 
concentration of potassium, 4.4 mmol/L (normal range: 
3.5-5.5 mmol/L), sodium 141 mEq/L (normal range: 135-
148 mEq/L), chloride 107 mEq/L (normal range: 95-108 
mEq/L His kidney function was normal. There was a slight 
increase in creatinine phosphokinase (CPK) (238 U/L) 
where the normal range extends to 170 U/L).
This patient’s mental state, including thought processes, 
mood, and intellectual function, was in excellent condi-
tion. The physical exam was unremarkable, except that 
arterial pulsations were weaker in both legs. Blood pres-
sure was 140/75 mmHg, and the pulse was 55/min. An 
ultrasound of the abdominal aorta, kidneys and large ar-
teries showed no evidence of abdominal aortic aneurism, 
but atherosclerotic plaques and ectasia of the distal aorta 
and common iliac arteries were noted. No abnormalities 
were found on electromyography of the legs.
At this time (October 2011), simvastatin was discontin-
ued and pravastatin was prescribed (80 mg/day, taken at 
night). Other medications (lisinopril 10 mg/day, atenolol 
25 mg/day and aspirin 100 mg/day) were continued as 
before. Six weeks later, at the follow-up visit, the patient 
reported that his leg pains at night and pain after brisk 
walking had completely stopped. At this time, the lipid risk 
panel was similar to that when the patient was on simvas-
tatin, CPK was within normal range, and HDL cholesterol 
was still lower than optimal (Table 1). Four months after 
the substitution of pravastatin for simvastatin, the patient 
reported that he had neither leg pains at night nor pain 
provoked by brisk walks.
DISCUSSION
Simvastatin, in a dose of 40 mg/day, was initially well toler-
ated by our patient. It effectively reduced elevated hyperli-
pidemia for several years before leg pain at night appeared. 
Because this type of pain is common among elderly people 
[2], the patient did not think that it was connected to sim-
vastatin treatment. We observed earlier that reducing the 
dose of simvastatin to 10 mg/day or discontinuing the drug 
entirely eliminated nocturnal leg cramps [3]. However, be-
cause we considered that there could be rebound effects 
related to the vascular effects, we prescribed pravastatin 
instead of simvastatin. This substitution resulted in an ad-
equate lipid-lowering effect but did not cause the leg pain.
Simvastatin is a prodrug; it is hydrolyzed to its active form, 
simvastatin acid, which is a specific inhibitor of 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase. This 
enzyme is an important component of the biosynthetic 
pathway for cholesterol. Because of their effectiveness and 
well-established safety profiles [4-6], simvastatin and other 
HMG-CoA reductase inhibitors are the mainstays for man-
agement of high cholesterol and associated cardiovascular 
complications. Statins may have similar side effects, but these 
effects do not always occur at the same rate among the vari-
ous statins. Muscle toxicity is the most significant adverse 
effect related to statins [7,8]. It includes myalgia, myopathy, 
and rhabdomyolysis. The pharmacokinetic disposition of 
simvastatin, but not pravastatin, depends upon individual 
differences in tissue content of cytochrome P450 (CYP) 3A4 
oxidases [9], and it may be influenced by CYP 3A4 inhibitors, 
such as ketoconazole, verapamil, mibefradil, and grapefruit. 
None of these known inhibitors were factors for our patient.
An association between single-nucleotide polymorphisms 
located within SLCO1B1 gene on the chromosome 12 and es-
tablished myopathy was recently reported for patients treated 
with simvastatin [10]. Similar findings have been reported for 
type 2 diabetic patients treated with simvastatin. However, no 
such association has been recorded with pravastatin.
The strong, but short lasting, leg cramps that affected our 
patient were not associated with significant increase of se-
rum CPK level. These painful muscle cramps were probably 
caused by an inadequate vascular supply to the calf and foot 
muscles. We do not know the mechanism of these changes 
caused by simvastatin. Perhaps a combination of advanced 
age, glucose intolerance, and atherosclerotic changes create 
a predisposition for the simvastatin-induced nocturnal leg 
cramps. Mentioned differences between the two statins may 
contribute to better tolerance of pravastatin.
Table 1. Lipid panel before simvastatin, and during simvastatin and pravastatin treatments. Fasting levels of lipids are expressed in mmol/L.
Lipid* Before simvastatin 
treatment
Six weeks of simvastatin 
treatment
The last day of 
simvastatin treatment
Six weeks of pravastatin
treatment
Total cholesterol 4.31 2.92 3.41 3.82
Triglyceride 2.65 1.72 1.73 1.49
LD cholesterol (calc.) 2.71 1.37 1.78 2.19
HDL cholesterol 0.64 0.77 0.82 0.95
Non-HDL cholesterol - - 2.58 2.87
* According to the National Cholesterol Education Program guideline, desirable values for cholesterol are <5.15 mmol/L, triglyceride <1.7 mmol/L, LDL <2.59 mmol/L, 
HDL >1.05 mmol/L, and non-HDL <3.36 mmol/L.
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КРАТАК САДРЖАЈ
Увод Ста  ти  ни има  ју сли  чан про  фил не  же  ље  них деј  ста  ва, али 
по  сто  је раз  ли  ке у сте  пе  ну уче  ста  ло  сти из  ме  ђу по  је  ди  них 
ста  ти  на. У члан  ку је при  ка  зан слу  чај код ко  јег је ми  шић  на 
ток  сич  ност иза  зва  на сим  ва  ста  ти  ном не  ста  ла ка  да је уме  сто 
ње  га у те  ра  пи  ју уве  ден пра  ва  ста  тин.
При  каз бо  ле  сни  ка Му  шка  рац стар 74 го  ди  не, не  пу  шач, 
по  вре  ме  но је имао ја  ке ноћ  не бол  не гр  че  ве у но  га  ма. Жа-
лио се и на бол  не гр  че  ве у но  га  ма при бр  зом хо  да  њу или 
тр  ча  њу. По  што је ли  пид  ни ста  тус био из  ван оп  ти  мал  ног, а и 
због ин  фарк  та ми  о  кар  да ра  ни  јих го  ди  на, ле  кар је пре  пи  сао 
сим  ва  ста  тин (40 mg днев  но). Бо  ле  сник је узи  мао тај лек осам 
го  ди  на. Епи  зо  де ноћ  них бо  ло  ва су по  че  ле пре две го  ди  не, 
а за  хва  та  ли су јед  ну или дру  гу но  гу. Пре че  ти  ри ме  се  ца те-
ра  пи  ја сим  ва  ста  ти  ном је за  ме  ње  на пра  ва  ста  ти  ном (80 mg 
днев  но). Шест не  де  ља ка  сни  је ноћ  них и бо  ло  ва ко  ји су се 
ја  вља  ли при бр  зом хо  да  њу ни  је ви  ше би  ло. Че  ти  ри ме  се  ца 
на  кон за  ме  не сим  ва  ста  ти  на пра  ва  ста  ти  ном бо  ле  сник и да-
ље ни  је осе  ћао ни  ка  кве те  го  бе.
За  кљу  чак Бол  ни гр  че  ви но  гу ве  ро  ват  но су иза  зва  ни нео-
д  го  ва  ра  ју  ћим снаб  де  ва  њем кр  вљу ми  ши  ћа пот  ко  ле  ни  це 
и сто  па  ла. Мо  гу  ће је да је ком  би  на  ци  ја ста  ри  јег жи  вот  ног 
до  ба и ате  ро  скле  рот  ских про  ме  на би  ла пре  ди  спо  зи  ци  ја за 
по  ја  ву гр  че  ва но  гу иза  зва  них сим  ва  ста  ти  ном. Пра  ва  ста  тин 
се раз  ли  ку  је од сим  ва  ста  ти  на јер га не ме  та  бо  ли  зу  ју ци  то-
хром P450 (CYP) 3A4 ок  си  да  зе, као што је слу  чај са сим  ва  ста-
ти  ном. По  ред то  га, ми  о  па  ти  ја иза  зва  на сим  ва  ста  ти  ном, али 
не и пра  ва  ста  ти  ном, по  ве  за  на је с по  ли  мор  фи  змом јед  ног 
ну  кле  о  ти  да ко  ји је ло  ка  ли  зо  ван у ге  ну SLCO1B1 два  на  е  стог 
хро  мо  зо  ма. Те раз  ли  ке из  ме  ђу два ле  ка мо  гле би до  при  не  ти 
бо  љем под  но  ше  њу пра  ва  ста  ти  на код бо  ле  сни  ка при  ка  за  ног 
у овом члан  ку.
Кључ  не ре  чи: ста  ти  ни; сим  ва  ста  тин; пра  ва  ста  тин; ноћ  ни 
гр  че  ви у но  га  ма
Ноћни грчеви у ногама изазвани симвастатином нестају после супституције 
правастатином
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